The writing group was chosen from the membership of the International Society for Heart
and Lung Transplantation (ISHLT), the Association of European Pediatric and Congenital …

Pulmonary arterial hypertension (PAH) is no longer an orphan disease. There are three
different classes of drugs for the treatment of PAH that are currently being used and an …

Rationale: Pulmonary arterial hypertension (PAH) is a life-shortening condition. The
European Society of Cardiology and European Respiratory Society and the REVEAL (North …

Objective To quantify right ventriculo-arterial coupling in pulmonary hypertension by
combining standard right heart catheterisation (RHC) and cardiac magnetic resonance …

Pulmonary hypertension associated with left heart disease is the most common form of
pulmonary hypertension encountered in clinical practice today. Although frequently a target …

Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy,
characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and …

Although changes in the pulmonary vasculature are the primary cause of pulmonary arterial
hypertension (PAH), severity of symptoms and survival are strongly associated with right …

Background Late gadolinium enhancement (LGE) occurs at the right ventricular (RV)
insertion point (RVIP) in patients with pulmonary hypertension (PH) and has been shown to …

New and emerging therapies might provide benefit in patients with pulmonary arterial
hypertension. Their efficacy and safety will be compared with existing combination therapies …

During recent years, right ventricular (RV) structure and function have been found to be an
important determinant of outcome in different cardiovascular and also pulmonary diseases …